Clinical Trials Logo
  1. Home
  2. Methamphetamine Dependence
  3. NCT00519259
  4. Details
NCT00519259 Clinical Trial

Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

Methamphetamine Dependence Clinical Trial

Official title:
Tolerability, Safety, and Pharmacokinetics of Repeated Sublingual Doses of Lobeline

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT00519259
Other study ID # NIDA-CPU-0009-1
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received June 29, 2006
Last updated January 10, 2017
Start date February 2006

Study information
Verified date June 2006
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 12
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Must be able to provide written informed consent

- Must have a body mass index between 18 and 30

- Have no medical contraindications as determined by medical history, physical exam, ECG, hematology and blood chemistry profile, and urinalysis

- Must have a negative drug test at screening and admission

- If female of child bearing potential, must agree to use birth control

Exclusion Criteria:

- Please contact the site for more information

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Lobeline

Locations
Country Name City State
United States Langley Porter Psychiatric Institute San Francisco California

Sponsors (1)
Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Tolerability
Secondary Safety
Secondary Pharmacokinetic parameters
Secondary Cardiovascular responses
Secondary Psychological effects of lobeline
See also
  Status Clinical Trial Phase
Terminated NCT01813656 - An Study of Aripiprazole in the Treatment of Methamphetamine Dependence Phase 4
Completed NCT00984360 - Study of Naltrexone for Methamphetamine Addiction Phase 2
Completed NCT01685463 - Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving N/A
Completed NCT00569374 - Safety and Tolerability of Modafinil for Methamphetamine Dependence Phase 2
Completed NCT01967381 - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse Early Phase 1
Completed NCT01354470 - A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence Phase 2
Active, not recruiting NCT01044238 - Methylphenidate to Treat Methamphetamine Dependence Phase 2
Completed NCT01215929 - Studying Amphetamine Withdrawal in Humans Phase 2
Terminated NCT01019707 - Safety Assessment of Atomoxetine With MA IV Administration Phase 1
Completed NCT00227123 - A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence N/A
Recruiting NCT02568878 - Creatine for Depressed Male and Female Methamphetamine Users Phase 3
Completed NCT01011829 - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence Phase 2
Completed NCT01007539 - Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence Phase 3
Completed NCT01062451 - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence Phase 1
Completed NCT00687713 - Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence Phase 2
Completed NCT01063205 - NAC as a Potential Treatment for Methamphetamine Dependence Phase 1
Completed NCT02058966 - Pilot Study of Entacapone for Methamphetamine Abuse Early Phase 1
Completed NCT00332605 - N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence Phase 2
Completed NCT01860807 - Trial of Ibudilast for Methamphetamine Dependence Phase 2
Terminated NCT01813643 - A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis Phase 4